Equities

AbbVie Inc

0QCV:LSE

AbbVie Inc

  • Price (USD)161.57
  • Today's Change-0.23 / -0.14%
  • Shares traded2.51k
  • 1 Year change10.02%
  • Beta--
Data delayed at least 20 minutes, as of May 14 2024 19:09 BST.
More ▼

Profile data is unavailable for this security.

About the company

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

  • Revenue in USD (TTM)54.40bn
  • Net income in USD5.95bn
  • Incorporated2012
  • Employees50.00k
  • Location
    AbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
  • Phone+1 (847) 932-7900Fax+1 (302) 655-5049
  • Websitehttps://www.abbvie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QCV:LSE since
announced		Transaction
value
Cerevel Therapeutics Holdings IncAnnounced06 Dec 202306 Dec 2023Announced11.76%8.62bn
ImmunoGen IncDeal completed30 Nov 202330 Nov 2023Deal completed16.66%10.22bn
Data delayed at least 20 minutes, as of May 14 2024 19:09 BST.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.